Martin-Du Pan R C, Aubert M L, Biondo M, Campana A
Clinique de Stérilité et d'Endocrinologie de la Reproduction, Hôpital Cantonal Universitaire de Genève, Suisse.
J Gynecol Obstet Biol Reprod (Paris). 1995;24(4):357-61.
Human chorionic gonadotrophin (hCG), human menopausal gonadotrophins (hMG) and somatotrope hormone (STH) were used for three months to induce spermatogenesis in a patient with azoospermia following hypophysectomy for Cushing's syndrome. Azoospermia reappeared when testosterone was substituted for hCG, despite continued treatment with FSH and STH. In a second patient who had undergone hypophysectomy for a craniopharyngioma presenting residual oligospermia, STH alone was uneffective in improving the sperm count. In both patients, the level of IGF-1 in seminal fluid was unchanged by STH despite increased serum IGF-1. The use of STH to induce spermatogenesis is discussed in light of its capacity to increase testosterone synthesis is response to hCG.
人绒毛膜促性腺激素（hCG）、人绝经期促性腺激素（hMG）和生长激素（STH）被用于一名因库欣综合征接受垂体切除术后无精子症的患者，以诱导精子发生，为期三个月。尽管继续使用促卵泡激素（FSH）和生长激素进行治疗，但当用睾酮替代hCG时，无精子症再次出现。在第二例因颅咽管瘤接受垂体切除术且仍存在少精子症的患者中，单独使用生长激素并不能有效提高精子计数。在这两名患者中，尽管血清胰岛素样生长因子-1（IGF-1）水平升高，但生长激素并未改变精液中IGF-1的水平。鉴于生长激素在对hCG的反应中增加睾酮合成的能力，对其用于诱导精子发生进行了讨论。
